Xponance Inc. Raises Holdings in Zoetis Inc. $ZTS

Xponance Inc. lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 14.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 124,473 shares of the company’s stock after buying an additional 15,768 shares during the quarter. Xponance Inc.’s holdings in Zoetis were worth $18,213,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Savvy Advisors Inc. lifted its position in shares of Zoetis by 54.0% during the second quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock valued at $495,000 after buying an additional 1,114 shares during the last quarter. CIBC Asset Management Inc increased its holdings in shares of Zoetis by 4.3% in the third quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock valued at $36,745,000 after purchasing an additional 10,434 shares during the period. Mitsubishi UFJ Trust & Banking Corp lifted its stake in Zoetis by 6.5% during the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock valued at $43,235,000 after acquiring an additional 18,040 shares during the period. Ninety One UK Ltd boosted its holdings in Zoetis by 19.6% in the third quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock valued at $163,751,000 after purchasing an additional 183,686 shares during the last quarter. Finally, Quilter Plc raised its position in Zoetis by 10.2% during the third quarter. Quilter Plc now owns 438,959 shares of the company’s stock valued at $64,228,000 after acquiring an additional 40,615 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Up 0.5%

Shares of ZTS opened at $129.65 on Friday. The company’s 50-day moving average price is $125.88 and its 200 day moving average price is $134.28. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $177.00. The firm has a market cap of $54.73 billion, a P/E ratio of 21.54, a price-to-earnings-growth ratio of 1.97 and a beta of 0.96.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 1.6%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Weiss Ratings lowered Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, January 28th. Stifel Nicolaus cut their price objective on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research report on Tuesday, November 18th. Barclays began coverage on Zoetis in a research report on Monday, December 8th. They set an “equal weight” rating and a $136.00 target price on the stock. HSBC set a $140.00 price target on shares of Zoetis in a report on Wednesday, December 10th. Finally, Bank of America upped their price objective on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, February 13th. Five equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.